Minal Mehta

792 total citations · 1 hit paper
19 papers, 383 citations indexed

About

Minal Mehta is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Minal Mehta has authored 19 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Minal Mehta's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Minal Mehta is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Minal Mehta collaborates with scholars based in United States, Spain and China. Minal Mehta's co-authors include Danny Nguyen, Jianchang Lin, Shu Jin, Huamao Mark Lin, Veronica Bunn, Suresh S. Ramalingam, Pasi A. Jänne, Tarek Mekhail, Gregory J. Riely and Enriqueta Felip and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Minal Mehta

19 papers receiving 374 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

2021 196 citations Caicun Zhou, Suresh S. Ramalingam et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minal Mehta United States	9	310	290	93	85	34	19	383
Greg Andrew Durm United States	11	324 1.0×	375 1.3×	97 1.0×	56 0.7×	60 1.8×	52	488
Waree Rinsurongkawong United States	11	280 0.9×	235 0.8×	100 1.1×	151 1.8×	42 1.2×	30	407
Landon C. Brown United States	12	252 0.8×	195 0.7×	108 1.2×	89 1.0×	49 1.4×	29	372
B.C. Cho South Korea	8	232 0.7×	204 0.7×	90 1.0×	47 0.6×	15 0.4×	33	280
Claudio Sini Italy	15	227 0.7×	235 0.8×	163 1.8×	128 1.5×	48 1.4×	28	440
Umair Majeed United States	5	159 0.5×	149 0.5×	95 1.0×	81 1.0×	19 0.6×	27	295
Yun Fan China	13	337 1.1×	479 1.7×	86 0.9×	83 1.0×	66 1.9×	52	580
Adel Zaatar Australia	5	376 1.2×	328 1.1×	126 1.4×	105 1.2×	13 0.4×	9	476
Sakiko Otani Japan	13	404 1.3×	465 1.6×	142 1.5×	92 1.1×	24 0.7×	45	613
Kevin Jao Canada	10	337 1.1×	293 1.0×	145 1.6×	142 1.7×	18 0.5×	23	476

Countries citing papers authored by Minal Mehta

Since Specialization

Citations

This map shows the geographic impact of Minal Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minal Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minal Mehta more than expected).

Fields of papers citing papers by Minal Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minal Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minal Mehta. The network helps show where Minal Mehta may publish in the future.

Co-authorship network of co-authors of Minal Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Minal Mehta. A scholar is included among the top collaborators of Minal Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minal Mehta. Minal Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2023). Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. Lung Cancer. 179. 107186–107186. 4 indexed citations

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2023). Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations. JTO Clinical and Research Reports. 4(10). 100558–100558. 25 indexed citations

Zhou, Caicun, Suresh S. Ramalingam, Huamao Mark Lin, et al.. (2022). Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort. Journal of Clinical Medicine. 12(1). 112–112. 9 indexed citations

Gupta, Neeraj, Han Witjes, Paul M. Diderichsen, et al.. (2022). Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study. Clinical Pharmacology & Therapeutics. 112(2). 327–334. 8 indexed citations

Christopoulos, Petros, S-H.I. Ou, Jianchang Lin, et al.. (2021). 1224P Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions. Annals of Oncology. 32. S972–S972. 2 indexed citations

Ou, S-H.I., Huamao Mark Lin, Yuping Yin, et al.. (2021). 1211P Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion. Annals of Oncology. 32. S964–S965. 2 indexed citations

Zhou, C., Suresh S. Ramalingam, Jian Fang, et al.. (2021). OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations. Journal of Thoracic Oncology. 16(3). S108–S108. 21 indexed citations

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2021). Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.. Journal of Clinical Oncology. 39(15_suppl). 9098–9098. 20 indexed citations

Jänne, Pasi A., Suresh S. Ramalingam, James Chih‐Hsin Yang, et al.. (2021). FP09.01 Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy. Journal of Thoracic Oncology. 16(10). S960–S960. 2 indexed citations

10.

Zhou, Caicun, Suresh S. Ramalingam, Tae Min Kim, et al.. (2021). Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer. JAMA Oncology. 7(12). e214761–e214761. 196 indexed citations breakdown →

11.

Hida, Toyoaki, et al.. (2021). 1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients. Annals of Oncology. 32. S981–S981. 1 indexed citations

12.

Ramalingam, Suresh S., Caicun Zhou, Tae Min Kim, et al.. (2021). Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.. Journal of Clinical Oncology. 39(15_suppl). 9014–9014. 18 indexed citations

13.

Spira, Alexander I., Joel W. Neal, Zofia Piotrowska, et al.. (2021). OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy. Journal of Thoracic Oncology. 16(10). S873–S874. 3 indexed citations

14.

Butler, Marcus O., Caroline Robert, Sylvie Négrier, et al.. (2019). ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy. Annals of Oncology. 30. v560–v561. 2 indexed citations

15.

Butler, Marcus O., Caroline Robert, Sylvie Négrier, et al.. (2019). ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.. Journal of Clinical Oncology. 37(15_suppl). TPS9599–TPS9599. 7 indexed citations

16.

Cohen, Ezra E.W., Kevin J. Harrington, David S. Hong, et al.. (2018). A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results. Annals of Oncology. 29. viii372–viii372. 30 indexed citations

17.

Cohen, Ezra E.W., David S. Hong, William N. William, et al.. (2017). Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 28. v403–v403. 19 indexed citations

18.

Hong, David S., Gerald S. Falchook, Carl Cook, et al.. (2016). A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN. Annals of Oncology. 27. vi360–vi360. 7 indexed citations

19.

Schiller, Joan H., Suzanne E. Dahlberg, Minal Mehta, & David H. Johnson. (2009). A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598. Journal of Clinical Oncology. 27(15_suppl). 7503–7503. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact